Found 489 hits.
|
217. |
Muñoz, M., Kiefer, L. A., Pereira, M. P., Bizjak, M., and Maurer, M.+: New insights into chronic inducible urticaria. Curr. Allergy Asthma Rep. 2024: 24; 457-469. IF: TBD (IF 2023: 5.40) |
r.217
| 113. | Maurer, M., Giménez-Arnau, A. M., and Zuberbier, T.: What is new and upcoming in the world of chronic urticaria? J. Eur. Acad. Dermatol. Venereol. 2016: 30, Suppl. 5; 5-6. IF: 3.52 |
| 306 | Bonnekoh, H., Ohanyan, T., Lenze, D., Krause, K., Maurer, M. Zuberbier, T.*, and Siebenhaar, F.*+: Development of tripe palms and soles in a patient with long pre-existing systemic mastocytosis and newly developed non-small cell lung cancer. J. Eur. Acad. Dermatol. Venereol. 2018: 32; e151-e153. IF: 5.11 |
|
187. |
Zuberbier, T.+, Bernstein, J. A., and Maurer, M.: Chronic spontaneous urticaria guidelines: what is new? J. Allergy Clin. Immunol. 2022: 150; 1249-1255. IF: 14.20 |
r.187
|
503. |
Ahsan, D. M., Altrichter, S., Gutsche, A., Bernstein, J. A., Altunergil, T., Brockstaedt, M., Maurer, M.+, Weller, K., and Terhorst-Molawi, D.: Development of the cold urticaria activity score. Allergy 2022: 77; 2509-2519. IF: 12.40 |
o.503
| 59. | Kirchhoff, D., Kaulfuss, S., Maurer, M., and Zollner, T. M.: Mast cells in endometriosis: Guilty or innocent bystanders? Expert Opin. Ther. Targets 2012: 16; 237-241. IF: 4.13 |
| 65. | Church, M. K. and Maurer, M.: H1-antihistamines and urticaria: how can we predict the best drug for our patient? Clin. Exp. Allergy 2012: 42; 1423-1429. IF: 4.78 |
| 330 | Banerji, A.+, Riedl, M. A., Bernstein, J. A., Cicardi, M., Longhurst, H. J., Zuraw, B. L., Busse, P. J., Anderson, J., Magerl, M., Martinez-Saguer, I., Davis-Lorton, M., Zanichelli, A., Li, H., Craig, T., Jacobs, J., Johnston, D. T., Shapiro, R., Yang, W. H., Lumry, W. R., Manning,M. E., Schwartz, L. B., Shennak, M., Soteres, D., Zaragoza-Urdaz, H., Gierer, S., Smith, A. M., Tachdjian, R., Wedner, J., Hebert, J., Rehman, S. M., Staubach, P., Schranz, J., Baptista, J., Nothaft, W., and Maurer, M.: Effect of Lanadelumab compared with placebo on prevention of hereditary angioedema attacks: a randomized clinical trial. JAMA 2018: 320; 2108-2121. IF: 51.27 |
| 106. | Schmetzer, O., Valentin, P., Church, M. K., Maurer, M., and Siebenhaar, F.: Murine and human mast cell progenitors. Eur. J. Pharmacol. 2016: 778; 2-10. IF: 2.89 |
r.106
| 323 | Aygören-Pürsün, E.*+, Bygum, A.*, Grivcheva-Panovska, V., Magerl, M., Graff, J., Steiner, U., Fain, O., Huissoon, A., Kinaciyan, T., Farkas, H., Lleonart, R., Longurst, H., Rae, W., Triggiani, M., Aberer, W., Cancian, M., Zanichelli, A., Smith, W. B., Baeza, M. L., Du-Thanh, A., Gompels, M., Gonzalez-Quevedo, T., Greve, J., Guilarte, M., Katelaris, C., Dobo, S., Cornpropst, M., Clemons, D., Fang, Lei, Collis, P., Sheridan, W., Maurer, M.*, Cicardi, M.*: Oral plasma kallikrein inhibitor for prophylaxis in hereditary angioedema. New Engl. J. Med. 2018: 379; 352-362. IF: 70.67 |